Interaction Between Prediabetes and the ABO Blood Types in Predicting Postsurgical Esophageal Squamous Cell Carcinoma-Specific Mortality: The FIESTA Study

Abstract

Background: We aimed to investigate the interaction between prediabetes and the ABO blood types in predicting esophageal squamous cell carcinoma (ESCC)-specific mortality by analysing data from the FIESTA study on normal/prediabetic patients with ESCC.Methods: Total 1,857 normal/prediabetic patients with ESCC who underwent three-field lymphadenectomy between January 2000 and December 2010 and survived hospitalization were analyzable, with follow-up beginning in 2000 and ending in 2015.Results: At the end of the follow-up, there were 1,161 survivors and 696 non-survivors. The follow-up time ranged from 0.5 to 180 months. The cumulative survival rates in normal patients were obviously better than in prediabetic patients. The cumulative survival rates were significantly higher in normal patients than in prediabetic patients for the blood types O and A (Log-rank test P < 0.05), while no significance was detected for the blood types B and AB. Adjusted risk estimates for ESCC-specific mortality for prediabetic patients relative to normal patients were statistically significant in the blood type B− group (hazard ratio [HR]: 1.71; 95% confidence interval [CI]: 1.33–2.20; P < 0.001), but not in the blood type B+ group (HR: 1.12; 95% CI: 0.77–1.64; P = 0.5544).Conclusions: Our findings indicate that prediabetes can predict the significant risk of ESCC-specific mortality in Chinese Han patients with the blood types O and A.

Prognostic Role of ABO Blood Type in Operable Esophageal Cancer: Analysis of 2179 Southern Chinese Patients

“…The ABO blood group has been associated with the risk of esophageal cancer, but the prognostic value of ABO blood group and each ABO blood type has not been established because the studies have yielded conflicting results (13)(14)(15)(16)(17). The reasons for this may be the absence of large cohort clinical studies, the results varying by different geographic areas and ethnic groups, patients receiving neoadjuvant therapy enrolled in some of the studies, and potential confounding variables not controlled in some studies.…”

“…Moreover, ABO blood group was identified to be associated with the risk of esophageal cancer (9)(10)(11)(12). Nevertheless, ABO blood group has not yet been demonstrated to independently predict survival of esophageal cancer in previous studies (13)(14)(15)(16)(17). Some studies have found no significant association between ABO blood group and survival (13,14), whereas others indicate ABO blood group had significantly different survival, but not independently associated with prognosis for all patients (16).…”

Prediction of presurgical metabolic syndrome for gastric cancer‐specific mortality is more evident in smokers: The FIESTA study

“…The FIESTA study was initiated by Fujian Provincial Cancer Hospital in January 2000, with the aims to optimize presurgical risk factors and predict cancer‐specific mortality of common digestive system malignancies, including esophageal cancer, gastric cancer, and colorectal cancer. 11 , 14 , 15 , 18 , 19 , 20 , 21 The Ethics Committee of Fujian Provincial Cancer Hospital approved the implementation of the FIESTA study (Approval Number: SQ2015‐070‐01).…”

“…Total 3012 patients with gastric cancer who received radical resection of primary gastric cancer for the first time, underwent no presurgical and postsurgical chemotherapy/radiotherapy, and were consecutively recruited from January 2000 to December 2010, with the latest follow‐up ended on December 31, 2015, were eligible for inclusion, as previously described. 11 , 13 , 14 , 15 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 The reason for us to exclude patients with presurgical and postsurgical chemotherapy/radiotherapy is due to its significant impact on survival outcomes.…”